

1 Title: Effects of chemotherapy on skeletal muscle mitochondrial oxidative capacity using  
2 Near-Infrared Spectroscopy (NIRS): Protocol paper for an observational mixed model repeated  
3 measures design in patients with breast and gynecological cancer

4 Evaluation of mitochondrial oxidative capacity during chemotherapy using NIRS

5

6 Funding: This study was partially funded through the Prisma Health Cancer Institute Office of  
7 Philanthropy and Partnership and the University of South Carolina School of Medicine  
8 Greenville Summer Scholars Program. Funders played no role in study design; collection,  
9 management, analysis, and interpretation of data; writing of the report; and the decision to  
10 submit the report for publication, including whether they will have ultimate authority over any of  
11 these activities.

12

13 Competing Interests: The authors have declared no competing interests.

14

15 Data availability: All relevant data resulting from protocol execution of this study will be made  
16 available upon study completion.

17

18

19 Randolph Hutchison<sup>1</sup>, Shannon Smith<sup>2</sup>, Chloe Caudell<sup>2</sup>, Sara Biddle<sup>3</sup>, W. Larry Gluck<sup>3</sup>, Jennifer  
20 Trilk<sup>2\*</sup>

21

22

23 1. Department of Health Sciences, Furman University, Greenville, South Carolina, United States  
24 of America

25 2. Department of Biomedical Sciences, University of South Carolina School of Medicine  
26 Greenville, Greenville, South Carolina, United States of America

27 3. Cancer Institute, Prisma Health, Greenville, South Carolina, United States of America

28

29 \*Corresponding Author

30

31 Corresponding Author Email: [trilk@greenvillemed.sc.edu](mailto:trilk@greenvillemed.sc.edu)

32

## 33 **Abstract**

34

35           Chemotherapy-associated cachexia results in significant metabolic disturbances and loss  
36 of skeletal muscle. These physiologic effects increase fatigue, reduce physical functioning, and  
37 decrease quality of life in patients undergoing treatment for cancer. Mitochondrial dysfunction, a  
38 hallmark of metabolic disturbances in the skeletal muscle, has previously been studied in health  
39 participants using invasive muscle biopsy and/or time consuming, high-cost magnetic resonance  
40 spectroscopy. However, less is understood regarding mitochondrial dysfunction in patients with  
41 cancer. Near infrared spectroscopy (NIRS) is a non-invasive and cost-effective approach to  
42 assessing mitochondrial function of skeletal muscle by measuring oxygenated and deoxygenated  
43 hemoglobin and calculating the resulting tissue saturation index. NIRS has not yet been utilized  
44 to evaluate skeletal muscle change in cancer patients throughout chemotherapy. Therefore, we  
45 plan to conduct a single center clinical trial, using an observational mixed model repeated  
46 measures design to evaluate the change in mitochondrial oxidative capacity from baseline and  
47 throughout progression of an oncologist-prescribed chemotherapy regimen. Evaluation of  
48 mitochondrial function will be performed by taking real-time, NIRS in-situ measurements within  
49 the working muscle during stationary cycling exercise and subsequent recovery periods (e.g.  
50 “on” kinetics and “off” kinetics). We also plan to observe if there is a difference in mitochondrial  
51 oxidative capacity between different chemotherapy regimens across different patients. This pilot

52 study will provide information on the feasibility of capturing on/off kinetics mitochondrial  
53 function data longitudinally using NIRS in patients newly diagnosed with breast or  
54 gynecological cancer, provide preliminary data for future extramural funding, as well as inform  
55 the scientific community of results through dissemination via conferences and peer-reviewed  
56 publications.

57

58

59

60

61

62

63

64

65

66

67

68

69

## 70 **Introduction**

71           In the United States, more than 3.8 million women are currently receiving chemotherapy  
72 treatment, or have completed treatment, for breast or gynecological cancer [1]. Fortunately, over  
73 the past 25 years, the ability to detect and treat cancer has allowed breast cancer 5-year survivor  
74 rates to increase to 85 [1], ovarian cancer 5-year survivor rates to increase to 49% [2], and  
75 uterine cancer 5-year survivor rates to increase to 81% [3]. Unfortunately, while chemotherapy  
76 has improved survival rates amongst patients with breast and gynecological cancer, side effects  
77 include unfavorable body composition changes [4], increases in fatigue [5], reductions in  
78 physical functioning [6], and decreased quality of life (QOL) [7]. Most of these symptoms are  
79 due to chemotherapy-induced muscle wasting, also known as cachexia [8–10]. According to the  
80 National Cancer Institute, cachexia is estimated to occur in up to 80% of people with advanced  
81 cancer [8,11] and involves reduced size and content of mitochondria [12,13] and subsequent  
82 deterioration of mitochondrial function and its oxidative capacity associated with reduced energy  
83 production for physical functioning [9,10,14]. Cachexia has negative implications for patients  
84 with breast and gynecologic cancer; therefore, the increase in survivorship has been an increase  
85 in focus on understanding mechanisms of cachexia, such as mitochondrial dysfunction, with the  
86 aim of studying these mechanisms to understand how to improve quality of life for [10].

87           Previous studies have relied on more invasive tools to assess pathological progression of  
88 mitochondrial [15,16]. Muscle biopsies have been the gold standard assessment but cause

89 significant discomfort to the patient and may not represent *in vivo* activation of the skeletal  
90 working muscle tissue associated with [17]. Magnetic Resonance Spectroscopy (MRS) provides  
91 *in vivo* measurements but is cost prohibitive, time intensive, requires technical expertise, and  
92 competes with other clinical needs within the [17]. Metabolic ventilatory measures have been  
93 established as a gold standard in evaluation of pathophysiology with many chronic diseases  
94 except for large scale studies in cancer chemotherapy treatment [18–20]. These measurements  
95 could provide critical mechanistic understanding of oxygen delivery and utilization from a  
96 systematic whole-body approach [21]. To understand local skeletal muscle oxygen uptake  
97 kinetics, Near Infrared Spectroscopy (NIRS) has been validated with muscle biopsies and  
98 [22,23], as a low cost, non-invasive alternative assessing mitochondrial capacity in clinical [17].  
99 NIRS measurement of tissue oxygenation has been well studied and a thorough background on  
100 NIRS can be found elsewhere [17,22,24,25]. Briefly, biological tissue has a relatively good  
101 transparency for light in the near infrared region (700-1300 nm) and transmits photons through  
102 organs for *in situ* monitoring. The refracted light is converted into grams of oxyhemoglobin  
103 (O<sub>2</sub>Hb) and deoxyhemoglobin (HHb) based on the modified Beer-Lambert law[26]. NIRS  
104 devices with multiple transmitters at different distances from the receiver can calculate the  
105 Tissue Saturation Index (TSI)=O<sub>2</sub>Hb/(O<sub>2</sub>Hb + HHb) and reflects the percentage of measured  
106 blood that is oxygenated.

107         Assessment of mitochondrial capacity with NIRS includes studies of clinical populations  
108 with peripheral artery [27], chronic kidney [24], and neurologic diseases such as traumatic spinal  
109 cord injury and multiple [22], as well as comparisons with healthy [28] and assessment of age-  
110 related differences in skeletal muscle oxidative [17]. However, there is a dearth of NIRS studies

111 examining the effects of chemotherapy on skeletal muscle mitochondrial function in patients  
112 with cancer. Only two studies to our knowledge have utilized NIRS to measure muscle  
113 oxygenation variables in cancer survivors. Ederer, et al. [29] determined that [HHb] and  
114 [Hb]total were significantly lower in eight cancer survivors (all eight received chemotherapy and  
115 five received radiation) compared to healthy controls during exercise at ventilatory threshold.  
116 Grigoriadis, et al., [30] did not find a significant difference in muscle oxygenation variables  
117 between 23 patients with breast cancer (16 received chemotherapy, nineteen received radiation  
118 therapy, and 21 received hormonal therapy) and 23 participants who served as age and BMI  
119 matched controls. Recent literature of near infrared spectroscopy related to cancer primarily  
120 involves detection and identification of cancerous [31] or the use of near infrared light as a  
121 photoimmunotherapy [32]. Therefore, the hypothesized loss of mitochondrial capacity  
122 throughout chemotherapy treatment has not been studied longitudinally starting at baseline and  
123 tracking through the chemotherapy regimen in breast and gynecologic cancer patients with NIRS  
124 to date.

125         The aims of our study are to develop a protocol that 1) assesses mitochondrial  
126 dysfunction in cancer patients using exercise that is tolerable for the patients throughout the  
127 entire chemotherapy regimen and 2) explores the link between oxygen utilization at the muscular  
128 level via NIRS with whole body traditional metabolic ventilatory measures. This protocol will  
129 help us to observe the changes in mitochondrial functional capacity throughout an entire  
130 chemotherapy regimen for each patient and between different chemotherapy regimens over time.  
131 The protocol also will help us evaluate a potential correlation between subjective self-reported  
132 fatigue and perceived effort with corresponding objective metabolic and NIRS

133 measurements. The proposed study will help inform clinical decision makers in the oncology  
134 community regarding current chemotherapy regimens (based upon the National Comprehensive  
135 Cancer Network, NCCN) that patients may best tolerate for cachexia and fatigue.

136

## 137 **Materials and Methods**

138

### 139 **Organization and conduct**

140 The study protocol (Fig 1) was approved in July of 2021 by the Prisma Health  
141 Office of Human Subjects Protection Institutional Review Board Committee C (Protocol #  
142 Pro00110826). This study is sponsored through the Prisma Health Cancer Institute Office of  
143 Philanthropy and Partnership, the University of South Carolina School of Medicine Greenville  
144 Summer Scholars Program, and Furman University. The study sponsors and funders, played no  
145 role in study design; collection, management, analysis, and interpretation of data; writing of the  
146 report; and the decision to submit the report for publication, including whether they will have  
147 ultimate authority over any of these activities. This clinical trial has been registered with  
148 clinicaltrials.gov (Identifier: NCT006672497). Data collection started on July 26, 2021 and is  
149 ongoing through May 1, 2025.

150

(Insert Figure 1 here)

151

Fig 1. Schedule of Enrollments, Interventions, and Assessments.

## 152 **Experimental Design**

153           We will use an observational mixed model repeated measures design to longitudinally  
154 compare (pre-chemotherapy and throughout treatment) patients' skeletal muscle mitochondrial  
155 capacity of the vastus lateralis during stationary cycling. The study population will include  
156 female patients with breast or gynecological cancer. All testing will take place in the University  
157 of South Carolina School of Medicine Greenville's Human Performance Laboratory in the  
158 Prisma Health Cancer Institute.

159

## 160 **Sample Size**

161           We conducted a power analysis using Monte Carlo data simulation. We conducted the  
162 analysis using a mixed effects model with a fixed effect of chemotherapy cycle (time) and  
163 random effects for slope and intercept by participants with unstructured correlation [33–36]. Due  
164 to limited studies of NIRS measurements of patients with cancer, we used the conservative  
165 estimate of average recovery kinetics time constant ( $\tau$ ) of patients with chronic heart failure  
166 (25.35 seconds) and extrapolate average change in  $\tau$  throughout chemotherapy from Foulkes  
167 using results from Beever [37,38]. We assume that the random intercept will follow a gamma  
168 distribution with shape 1.57, a scale of 12.5, and a right shift of 13.25. Additional assumptions  
169 from Foulkes [38] and Beever [37] include the random slope is assumed to follow a normal  
170 distribution with an extrapolated standard deviation, as well as a normal distribution of the error



171 with standard deviation of 5.54 [39,40]. Analysis indicates that using a linear mixed effects  
172 model with sample size of at least  $n=30$  will be able to detect an effect of chemotherapy on  $\tau$   
173 with a power of 0.8. As the effect of chemotherapy type on  $\tau$  is unknown and unable to be  
174 approximated with data simulation, we are unable to conduct a full power analysis with the effect  
175 of chemotherapy type on  $\tau$  [29,41,42]. We assume that at least  $n=8$  of each chemotherapy type  
176 will be necessary to detect any differences in trajectory of  $\tau$  over time.

177

## 178 **Participants and Eligibility Requirements**

179 Participants recruited for this study will be female patients with breast cancer or  
180 gynecological cancer who will undergo a standard of care chemotherapy treatment as directed by  
181 their oncologist. Participants who are cleared by their oncologist to participate will be recruited  
182 through informative pamphlets and by oncology nurses trained in research and human subjects  
183 protection in Prisma Health System's Cancer Institute at Greenville Memorial Hospital, as well  
184 as Prisma Health affiliated oncologists' offices. Participants will be informed of the study's  
185 purpose, availability, timeline, and potentially associated minimal risks. Study staff will then  
186 obtain written informed consent from participants who agree to participate and before any data  
187 collection.

## 188 **Table1. Inclusion and Exclusion Criteria**

Inclusion Criteria
Female patients diagnosed with breast cancer or gynecological cancer without distant metastasis
Age > 20 years old
Able to perform exercise on a stationary cycle ergometer at moderate intensities for a maximum of 15 minutes
Hemoglobin (Hb) values > 10 g/dl at baseline
Alanine aminotransferase (ALT) and Aspartate transferase (AST) values less than 2.5X the upper limit of normal by institutional standards
Godin-Shephard Leisure Time Physical Activity Questionnaire (GLTEQ) score of 14 or higher
Exclusion Criteria
Metastatic breast or gynecological cancer

Clinically advanced cardiovascular disease or pulmonary disease or disease requiring continuous oxygen supplementation
Greater than 2 centimeters of subcutaneous adipose tissue on the anterior thigh
Inability to walk or stand, movement disorders, spinal cord injuries
Autoimmune disorders
Pregnant or breastfeeding
Mini-Mental State Examination (MMSE) score < 24
History of chemotherapy within 5 years prior to beginning participation

189

## 190 **Observational Protocol for First and Subsequent Visits**

191 Before starting chemotherapy, patients will undergo baseline testing that includes a  
192 lactate threshold test and an ON-OFF kinetics exercise test. The lactate threshold test will  
193 determine the power output (110% power at lactate threshold,  $P_{LT+}$ ) to be used for the follow-up  
194 baseline on-off kinetics test (ON-OFF). The ON-OFF kinetics test will take place at least 24  
195 hours after the lactate threshold test and consist of 3 cycles of 2 minutes at  $P_{LT+}$  and 2 minutes of

196 complete rest. Whole body O<sub>2</sub> uptake and CO<sub>2</sub> production will be captured via a metabolic cart  
197 during each test. Testing will take no more than 60 minutes per session, with a maximum study  
198 total of 300 minutes (about 5 hours) of participation per patient. Patients will be requested to  
199 avoid exercise and use of certain substances (tobacco, alcohol, caffeine, and contraindicated  
200 medications) 24 hours before testing. If laboratory baseline evaluation cannot be completed prior  
201 to the participant's treatment initiation, treatment will not be delayed, and patients will be waived  
202 from the study.

203 The independent variables in this study are drug regimen and number of chemotherapy  
204 treatments. The dependent variables in this study will be the changes in O<sub>2</sub>Hb, HHb, and TSI of  
205 the vastus lateralis, indicative of mitochondrial oxidative capacity after a bout of cycling. The  
206 specific variables measured will be the average recovery kinetics time constant,  $\tau$ , and TSI. Indirect  
207 calorimetry (O<sub>2</sub> uptake, CO<sub>2</sub> production) also will be captured at rest and during the ON/OFF  
208 kinetics as control variable comparisons for whole-body O<sub>2</sub> uptake and utilization.

## 209 **Instruments and Equipment**

210 The following devices will be utilized throughout the study: NIRS PortaMon by Artinis  
211 (Einsteinweg, Netherlands), Lode Corival (Groningen, Netherlands) stationary bike ergometer,  
212 Parvo Medics TrueOne 2400 (Salt Lake City, Utah) metabolic cart, Polar FT7 heart rate (HR)  
213 monitor (Kempele, Finland), Lactate Plus analyzer (Edina, Minnesota) and Sonosite Titan  
214 Portable Ultrasound System (Bloomfield, Connecticut) for adipose tissue thickness  
215 measurement.

## 216 **Fatigue and Quality of Life Surveys**

217 We will administer the Mini-Mental State Exam (MMSE) [43–45], Brief Fatigue  
218 Inventory (BFI) [46], Physical Activity Intake [47,48], PROMIS Global Health [49,50], and  
219 GLTPAQ surveys [51] prior to participant engagement in cycling exercises at the beginning of  
220 the first visit. We will administer BFI, PROMIS Global Health, and Physical Activity follow-up  
221 surveys at the beginning of each individual study session to assess any changes in cancer related  
222 fatigue associated with chemotherapy treatment that may develop throughout the study period.

223

## 224 **Visit #1: Lactate Threshold Test to Determine Power Output, NIRS**

### 225 **Orientation**

226 Participants will be asked to wear comfortable exercise clothes with shorts or equivalent  
227 so that the NIRS device can be placed directly on the skin. Participants will enter the  
228 performance lab and sit at rest in a chair. The NIRS device will be secured to the participant's  
229 leg at a standardized measurement of  $\frac{2}{3}$  distance from the anterior superior iliac spine to the  
230 lateral border of the patella [52]. This distance will be measured and marked medially and  
231 laterally on the patient's leg at a place that will not disrupt signal transmission. At this marked  
232 location, an ultrasound probe will be used to measure the subcutaneous adipose tissue thickness  
233 (ATT) between the epidermal layer and the muscular layer. If the ATT meets the  
234 inclusion/exclusion criteria, the NIRS device will be placed on the vastus lateralis. The  
235 ultrasound ATT measurement will be recorded. The NIRS device will be secured to the

236 participant's leg via double-sided non-latex adhesive tape applied between the device and the leg  
237 and lightly secured in position to the skin via non-latex tape. Pictures of the anatomical location  
238 of NIRS device placement with a tape measure from the center of the anterior border of the  
239 patella to the top of the NIRS device will be taken to standardize placement at every visit.

240 The patient will then complete the following questionnaires: contact information form,  
241 GLTPAQ, MMSE, BFI, PROMIS, and Physical Activity Form. After the completion of the  
242 questionnaires, study staff will review the GLTPAQ and Physical Activity form. Study staff will  
243 determine the initial power wattage for the test based on the answers to these surveys.

244 Sitting with both feet on the floor and legs uncrossed, manual blood pressure will be  
245 obtained two separate times, five minutes apart after 10 minutes of seated rest. Blood pressure  
246 measurements with an average of <140/<90 is to be considered safe to continue with testing [20].  
247 After the blood pressure measurement is obtained, the patient will have their temperature  
248 measured one time and their height and weight measured two times without shoes. The HR  
249 monitor will be fitted on the patient to continuously monitor HR throughout exercise. The rate of  
250 perceived exertion (RPE) scale will be explained to the patient. The patient will mount the  
251 stationary bike and study staff will help adjust the seat, handlebars, and pedals to the comfort of  
252 the patient. Study staff will then place a fitted silicone one-way rebreathing mask on the patient  
253 to measure their metabolic data using indirect calorimetry via the metabolic cart that captures  
254 expired gasses (O<sub>2</sub> and CO<sub>2</sub>). Capillary blood lactate levels will be obtained by finger stick for the  
255 lactate analyzer.

256 Participants will sit on the stationary bike for two minutes to capture expired gases and  
257 blood lactate levels at rest. At the end of rest, the patient will begin pedaling at a self-selected  
258 steady cadence between 60 and 100 RPMs at the initial power wattage determined by study staff.  
259 The patient will pedal at this cadence for the remainder of the test. Every three minutes, the  
260 power output will increase by 15 Watts. With thirty seconds remaining in each stage, blood  
261 lactate levels will be measured in duplicate and study staff will prompt the participant to quantify  
262 their effort using the RPE scale. When the duplicate blood lactate measurements exceed 4.0  
263 mmol/L, the participant will complete the current stage and end the test.

264 After completion of the test, study staff will calculate the power output that is equivalent  
265 to 1.1x the wattage at which patients' lactate exceeded 4.0 mmol/L ( $P_{LT+}$ ). This power output  
266 will be used as the exercise intensity for subsequent on-off kinetics testing.

267

## 268 **Visit #2+: On-Off Kinetics Testing**

269 Using the reference photo taken at the first visit, mark the NIRS device location  
270 and use the ultrasound to measure and record ATT. If the ATT measurement matches the ATT  
271 from the first visit, secure the NIRS device with tape as previously described. The participant  
272 will fill out the BFI, PROMIS Global Health, and Physical Activity Follow Up forms and update  
273 contact information if needed.

274 The participants will sit on the bike for a two-minute rest. Participants will begin  
275 pedaling for a warmup at 0 Watts for 2 minutes at a self-selected steady cadence of 60-100 RPM.

276 After the 2-minute warm up, the power output will increase to  $P_{LT+}$ . Participants will cycle at the  
277 same self-selected cadence for 2 minutes (“on-kinetics”). Thirty seconds before the end of the  
278 on-kinetics stage, participants will be asked their RPE. At the end of the 2-minute on-kinetics  
279 period, participants will stop pedaling and study staff will remove their non-measured leg from  
280 the pedal to rest on a box in a relaxed, extended position to aid in total relaxation and remove any  
281 additional movement of the measured leg. During the rest period, participants will remain in  
282 recovery sitting on the bike for 2 minutes (“off-kinetics” stage). Participants subsequently will  
283 start pedaling at their self-selected cadence for their next 2 minute “on-kinetics” stage, followed  
284 by another 2-min “off-kinetics” period. This cycle of exercise followed by rest, referred to as on-  
285 off kinetics, will repeat for a total maximum of 3 times, or unless the patient requests to stop.

286

## 287 **Outcome measures**

### 288 **Collection of biometrics at each visit**

289 Study staff will measure O<sub>2</sub>Hb, HHb, and TSI, via the NIRS PortaMon device during the  
290 on-off kinetics protocol. We also will measure ventilatory whole-body components including O<sub>2</sub>  
291 and CO<sub>2</sub> via the Parvomedics metabolic cart. Participants’ perceived exertion to the exercise will  
292 be measured via RPE during every exercise stage.

293 NIRS data will be collected using Artinis Medical System’s Oxysoft software at a  
294 frequency of 10hz. A differential pathlength factor (DPF) value of 4 will be selected, as  
295 recommended by Artinis (Einsteinweg, Netherlands). The PortaMon will be placed on the vastus



296 lateralis of participants for a period of at least 10 minutes prior to beginning exercise in  
297 accordance with the recommendation of Cortese L, et al. to allow calibration of the PortaMon  
298 [53].

299 Throughout data collection, researchers will closely observe for excess movement from  
300 participants that may affect the data collection. These sections will be removed from analysis.  
301 After data collection, a moving average with a filter width of 1.5 seconds will be applied to  
302 smooth leg movement artifacts that occurred during cycling. Data cleaning and analysis will be  
303 conducted using R (R Core Team, 2020) and RStudio (Rstudio Team, 2020).

304

## 305 **Data analysis and Statistical analysis**

306 Previous literature has shown that oxygenation levels at rest after moderate and/or high  
307 intensity exercise or after occlusion follows an asymptotic curve of the form [54]:

308

$$309 \quad y = A + (B_0 - A) e^{-t/\tau} \quad (2)$$

310

311 Where  $y$  is the oxygenation at time  $t$ ,  $A$  is the oxygenation as  $t$  approaches infinity,  $t$  is  
312 time measured in seconds,  $B_0$  is the value at  $t=0$ , and  $\tau$  is the time constant. For each rest period,  
313 we will run an asymptotic regression for O2Hb, HHb, and TSI by time in seconds to find the  
314 coefficient estimate for  $\tau$ .

315 Each data set will contain three rest periods; therefore, each data set will have three  $\tau$   
316 values for each variable. We will average the  $\tau$  values to obtain one average rest  $\tau$  for O<sub>2</sub>Hb,  
317 HHb, and TSI per data set. Since continuous wave NIRS devices measure oxy- and  
318 deoxyhemoglobin as changes from baseline, raw oxy- and deoxyhemoglobin values will have no  
319 meaning and are not comparable except when measured as changes over time or as  $\tau$  values.

320 We will analyze the  $\Delta O_2Hb$ ,  $\Delta HHb$ , and  $\Delta TSI$ , calculated as the change in steady state  
321 levels of O<sub>2</sub>Hb, HHb, and TSI respectively from work to rest, with steady state values calculated  
322 as the mean value of the final thirty seconds of the stage. For each data set of one on-off kinetics,  
323 there will be three work/rest period pairs therefore we will calculate three delta values and  
324 average the three delta values to obtain one delta value for O<sub>2</sub>Hb, HHb, and TSI per data set. The  
325 three work/rest transitions will allow for reliability testing with intraclass correlation coefficients.  
326 For participant data to be included in the final analysis, the participant will need to complete at  
327 least three on-off kinetic laboratory visits. Each participant will complete an on-off kinetics at  
328 least two weeks apart, but not more than one month apart in accordance with their prescribed  
329 chemotherapy treatment regimen. Each on-off kinetics will correspond with the first infusion of a  
330 chemotherapy cycle. To allow participants a maximum amount of time to recover from infusions  
331 before participating in exercise, the corresponding on-off kinetics takes place within 48 hours of  
332 the first infusion of the subsequent chemotherapy cycle. Since chemotherapy treatments vary  
333 depending on oncologist recommendation, each participant may complete different lengths of  
334 treatment, resulting in each participant having different numbers of data points. This will prevent  
335 us from using traditional statistical analysis such as repeated measures ANOVA. Since it is not  
336 time itself, but rather the compilation of chemotherapy infusions over time that we predict will

337 cause changes in measures of mitochondrial oxidative function, we will treat the number of  
338 chemotherapy cycles as an ordinal variable in this analysis. We will complete an analysis using  
339 mixed effects models to predict  $\tau$  and deltas from the number of chemotherapy treatments with a  
340 random intercept for patients.

341

## 342 **Data Management Plan**

343 Patient health information (PHI) will be obtained directly from the patient and the  
344 electronic medical record (EMR). This information will only be obtained after documented  
345 informed consent has been provided by the patient. PHI will be stored in the Prisma Health  
346 RedCap<sup>®</sup>, a HIPAA compliant cloud platform. All data will be housed within the Prisma Health  
347 system. Surveys and questionnaires will be stored in a locked file cabinet in a locked room in the  
348 Human Performance Laboratory.

349

## 350 **Trial Oversight**

351 This study has been approved by the Institutional Review Board at the Prisma Office of  
352 Research Compliance and Administration (ORCA). All adverse events (AE) and serious adverse  
353 events (SAE) will be recorded from the start of the visits, beginning with the first visit for lactate  
354 threshold testing and throughout completion of exercise visits, or when the participant has  
355 elected to no longer participate. The investigators will record and report all AE and SAE to the

356 IRB within 24 hours. Fatal or life threatening unexpected adverse reactions will be reported to  
357 Prisma Health IRB immediately.

358

## 359 **Discussion**

360 With limited studies of mitochondrial function (e.g. oxygen delivery and utilization)  
361 during cancer chemotherapy, opportunity exists to address mechanisms of cachexia and cancer-  
362 related fatigue using NIRS. To date, two main studies used NIRS with cancer populations.  
363 However, neither of the research teams collected data during active chemotherapy treatment, and  
364 they only measured steady-state values during exercise as opposed to collecting oxygen kinetics  
365 during recovery and exercise. Additionally, the independent variables included treatments  
366 additional to chemotherapy, including radiation and immunotherapy. The variation in  
367 independent variables may have been the reason for limited changes in the NIRS outcome  
368 variables. Ederer, et al [29] found significant differences in HHb and total hemoglobin with a  
369 limited sample size of 8 cancer survivors compared to matched controls, while Grigoriadis et al.  
370 [30] found no significant differences in any of the NIRS variables. Understanding oxygen  
371 delivery and utilization kinetics with ventilatory and local NIRS measurements during  
372 chemotherapy could unlock mechanistic understanding of mitochondrial dysfunction. Our study  
373 will be the first to recruit at least 30 patients diagnosed with cancer and capture both baseline and  
374 longitudinal NIRS measurements throughout the entire chemotherapy protocol.

375                   The study’s design must consider 1) exercise tolerance levels to obtain fatigue and  
376 recovery kinetics for patients going through chemotherapy and 2) rapid recruitment of patients  
377 for baseline measurements. We recognize that the level of conditioning our patients have at  
378 baseline may be reduced as treatment progresses. Therefore, we chose a protocol that was  
379 tolerable to patients, which is to cycle to 10% above their lactate threshold level; both before  
380 discontinuing the LT test and for the on/off kinetics tests. This intensity elicits an appropriate  
381 mitochondrial response in the exercising muscle while allowing for a reasonable exercise  
382 intensity that a patient can complete despite anticipated treatment deconditioning. Additionally,  
383 because patient recruitment will occur at the time of diagnosis, a team of referral coordinators,  
384 nurse navigators, and oncologists need to identify newly diagnosed patients, and be prepared,  
385 through a “chemo-teach”, to consent interested patients in a timely manner.

386                   A few limitations are to be considered regarding the validity of the PortaMon by Artinis  
387 Medical Systems. First, the device is designed to accurately penetrate 20 mm of depth through  
388 adipose tissue and into the muscle belly. If the subcutaneous adipose tissue thickness is greater  
389 than 20 mm, the infrared signal from the device will not penetrate the skeletal muscle body and  
390 be unable to obtain accurate measurements. Our protocol minimizes this concern by excluding  
391 participants who have greater than 20 mm adipose tissue subcutaneous to the vastus lateralis, and  
392 by standardizing device placement on the leg from test to test to increase reliability and validity  
393 of repeated measures measurements. Ambient light can interfere with the signal quality, however  
394 Oxysoft provides real-time data acquisition (DAQ) measurements. Using the manufacturer’s  
395 recommendation, channels with DAQ higher than 97% will be removed from analysis.

396 Results from this pilot study will provide information on the feasibility of capturing  
397 on/off kinetics mitochondrial function data longitudinally using NIRS in patients newly  
398 diagnosed with breast or gynecological cancer, provide preliminary data for future extramural  
399 funding, and inform the scientific community of results through dissemination via conference  
400 presentations and peer-reviewed publications.

## 401 **References**

- 402 1. DeSantis CE, Ma J, Goding Sauer A, Newman LA, Jemal A. Breast cancer statistics,  
403 2017, racial disparity in mortality by state. *CA Cancer J Clin.* 2017;67: 439–448.  
404 doi:10.3322/caac.21412
- 405 2. National Cancer Institute. Cancer Stat Facts: Ovarian Cancer. 23 Sep 2023.
- 406 3. American Society of Clinical Oncology. Uterine Cancer - Statistics. 26 Mar 2023.
- 407 4. Freedman RJH, Aziz N, Albanes D, Hartman T, Danforth D, Hill S, et al. Weight and  
408 Body Composition Changes during and after Adjuvant Chemotherapy in Women with  
409 Breast Cancer. *J Clin Endocrinol Metab.* 2004;89: 2248–2253. doi:10.1210/jc.2003-  
410 031874
- 411 5. Curt GA, Breitbart W, Cella D, Groopman JE, Horning SJ, Itri LM, et al. Impact of  
412 Cancer-Related Fatigue on the Lives of Patients: New Findings From the Fatigue  
413 Coalition. *Oncologist.* 2000;5. doi:10.1634/theoncologist.5-5-353
- 414 6. Perez EA, Suman VJ, Davidson NE, Kaufman PA, Martino S, Dakhil SR, et al. Effect of  
415 doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with  
416 breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant  
417 Trial. *Journal of Clinical Oncology.* 2004;22. doi:10.1200/JCO.2004.03.516
- 418 7. Kayl AE, Meyers CA. Side-effects of chemotherapy and quality of life in ovarian and  
419 breast cancer patients. *Current Opinion in Obstetrics and Gynecology.* 2006.  
420 doi:10.1097/01.gco.0000192996.20040.24
- 421 8. National Cancer Institute. Treating Cancer Cachexia: Progress Looks Possible. 2022.  
422 Available: <https://www.cancer.gov/about-cancer/treatment/research/cachexia>

- 423 9. Amano K, Baracos VE, Morita T, Miura T, Mori N, Tatara R, et al. The impact of  
424 cachexia on dietary intakes, symptoms, and quality of life in advanced cancer. *JCSM*  
425 *Rapid Commun.* 2022;5: 162–170. doi:10.1002/rco2.61
- 426 10. Beltrà ME, Pin F, Ballarò R, Costelli P, Penna F. Mitochondrial Dysfunction in Cancer  
427 Cachexia: Impact on Muscle Health and Regeneration. *Cells.* 2021;10: 3150.  
428 doi:10.3390/cells10113150
- 429 11. Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, et al. NCCN  
430 guidelines insights: breast cancer, version 1.2017. *Journal of the National Comprehensive*  
431 *Cancer Network.* 2017;15: 433–451.
- 432 12. Bohlen J, McLaughlin SL, Hazard-Jenkins H, Infante AM, Montgomery C, Davis M, et al.  
433 Dysregulation of metabolic-associated pathways in muscle of breast cancer patients:  
434 preclinical evaluation of interleukin-15 targeting fatigue. *J Cachexia Sarcopenia Muscle.*  
435 2018;9. doi:10.1002/jcsm.12294
- 436 13. Wilson HE, Stanton DA, Rellick S, Geldenhuys W, Pistilli EE. Breast cancer-associated  
437 skeletal muscle mitochondrial dysfunction and lipid accumulation is reversed by PPARG.  
438 *Am J Physiol Cell Physiol.* 2021;320. doi:10.1152/ajpcell.00264.2020
- 439 14. Guigni BA, Callahan DM, Tourville TW, Miller MS, Fiske B, Voigt T, et al. Skeletal  
440 muscle atrophy and dysfunction in breast cancer patients: Role for chemotherapy-derived  
441 oxidant stress. *Am J Physiol Cell Physiol.* 2018;315. doi:10.1152/ajpcell.00002.2018
- 442 15. Patterson MS, Chance B, Wilson BC. Time resolved reflectance and transmittance for the  
443 non-invasive measurement of tissue optical properties. *Appl Opt.* 1989;28: 2331–2336.  
444 doi:10.1364/ao.28.002331
- 445 16. Gorman GS, Schaefer AM, Ng Y, Gomez N, Blakely EL, Alston CL, et al. Prevalence of  
446 nuclear and mitochondrial DNA mutations related to adult mitochondrial disease. *Ann*  
447 *Neurol.* 2015;77: 753–759. doi:10.1002/ana.24362
- 448 17. Chung S, Rosenberry R, Ryan TE, Munson M, Dombrowsky T, Park S, et al.  
449 Near-infrared spectroscopy detects age-related differences in skeletal muscle oxidative  
450 function: promising implications for geroscience. *Physiol Rep.* 2018;6: e13588-n/a.  
451 doi:10.14814/phy2.13588
- 452 18. Jones LW, Eves ND, Haykowsky M, Freedland SJ, Mackey JR. Exercise intolerance in  
453 cancer and the role of exercise therapy to reverse dysfunction. *The Lancet Oncology.*  
454 2009. pp. 598–605. doi:10.1016/S1470-2045(09)70031-2

- 455 19. Jones LW, Eves ND, Mackey JR, Peddle CJ, Haykowsky M, Joy AA, et al. Safety and  
456 feasibility of cardiopulmonary exercise testing in patients with advanced cancer. *Lung*  
457 *Cancer*. 2007;55: 225–232. doi:10.1016/j.lungcan.2006.10.006
- 458 20. Sietsema KE, Stringer WW, Sue DY, Ward S. Wasserman & Whipp’s: Principles of  
459 Exercise Testing and Interpretation: Including Pathophysiology and Clinical Applications.  
460 6th ed. Zinner S, editor. Philadelphia, PA: Lippincott Williams & Wilkins; 2020.
- 461 21. Peel AB, Thomas SM, Dittus K, Jones LW, Lakoski SG. Cardiorespiratory fitness in  
462 breast cancer patients: a call for normative values. *Journal of the American Heart*  
463 *Association*. 2014. doi:10.1161/JAHA.113.000432
- 464 22. Ghatas MP, Holman ME, Gorgey AS. Methodological considerations for near-infrared  
465 spectroscopy to assess mitochondrial capacity after spinal cord injury. *J Spinal Cord Med*.  
466 2020;43: 623–632. doi:10.1080/10790268.2019.1631585
- 467 23. Van Beekvelt MCP, Colier WNJM, Wevers RA, Van Engelen BGM. Performance of  
468 near-infrared spectroscopy in measuring local O<sub>2</sub> consumption and blood flow in skeletal  
469 muscle. *J Appl Physiol*. 2001;90: 511–519. doi:10.1152/jappl.2001.90.2.511
- 470 24. Wilkinson TJ, White AEM, Nixon DGD, Gould DW, Watson EL, Smith AC.  
471 Characterising skeletal muscle haemoglobin saturation during exercise using near-infrared  
472 spectroscopy in chronic kidney disease. *Clin Exp Nephrol*. 2019;23: 32–42.  
473 doi:10.1007/s10157-018-1612-0
- 474 25. Willingham TB, McCully KK. In Vivo Assessment of Mitochondrial Dysfunction in  
475 Clinical Populations Using Near-Infrared Spectroscopy. *Front Physiol*. 2017;8.  
476 doi:10.3389/fphys.2017.00689
- 477 26. Cuartas-Vélez C, Veenstra C, Kruitwagen S, Petersen W, Bosschaart N. Optical density  
478 based quantification of total haemoglobin concentrations with spectroscopic optical  
479 coherence tomography. *Sci Rep*. 2021;11: 8680. doi:10.1038/s41598-021-88063-4
- 480 27. Baker WB, Li Z, Schenkel SS, Chandra M, Busch DR, Englund EK, et al. Effects of  
481 exercise training on calf muscle oxygen extraction and blood flow in patients with  
482 peripheral artery disease. *J Appl Physiol*. 2017;123: 1599–1609.  
483 doi:10.1152/jappphysiol.00585.2017
- 484 28. Brochhagen J, Coll Barroso MT, Baumgart C, Freiwald J, Hoppe MW. Non-invasively  
485 measured central and peripheral factors of oxygen uptake differ between patients with  
486 chronic heart failure and healthy controls. *BMC Cardiovasc Disord*. 2020;20: 378.  
487 doi:10.1186/s12872-020-01661-4



- 488 29. Ederer AK, Didier KD, Reiter LK, Brown M, Hardy R, Caldwell J, et al. Influence of  
489 Adjuvant Therapy in Cancer Survivors on Endothelial Function and Skeletal Muscle  
490 Deoxygenation. *PLoS One*. 2016;11: e0147691. doi:10.1371/journal.pone.0147691
- 491 30. Grigoriadis G, Sherman SR, Lima NS, Lefferts EC, Hibner BA, Ozemek HC, et al. Breast  
492 cancer survivors with preserved or rescued cardiorespiratory fitness have similar cardiac,  
493 pulmonary and muscle function compared to controls. *Eur J Appl Physiol*. 2022.  
494 doi:10.1007/s00421-022-04992-6
- 495 31. Vitorino R, Barros AS, Guedes S, Caixeta DC, Sabino-Silva R. Diagnostic and monitoring  
496 applications using near infrared (NIR) spectroscopy in cancer and other diseases.  
497 *Photodiagnosis and Photodynamic Therapy*. Elsevier B.V.; 2023.  
498 doi:10.1016/j.pdpdt.2023.103633
- 499 32. Wakiyama H, Kato T, Furusawa A, Choyke PL, Kobayashi H. Near infrared  
500 photoimmunotherapy of cancer; Possible clinical applications. *Nanophotonics*. De Gruyter  
501 Open Ltd; 2021. pp. 3135–3151. doi:10.1515/nanoph-2021-0119
- 502 33. DeBruine LM, Barr DJ. Understanding Mixed-Effects Models Through Data Simulation.  
503 *Adv Methods Pract Psychol Sci*. 2021;4: 251524592096511.  
504 doi:10.1177/2515245920965119
- 505 34. Cheng J, Edwards LJ, Maldonado-Molina MM, Komro KA, Muller KE. Real longitudinal  
506 data analysis for real people: Building a good enough mixed model. *Stat Med*. 2010;29:  
507 504–520. doi:10.1002/sim.3775
- 508 35. Guo Y, Logan HL, Glueck DH, Muller KE. Selecting a sample size for studies with  
509 repeated measures. *BMC Med Res Methodol*. 2013;13: 100. doi:10.1186/1471-2288-13-  
510 100
- 511 36. Kumle L, Vø ML-H, Draschkow D. Estimating power in (generalized) linear mixed  
512 models: An open introduction and tutorial in R. *Behav Res Methods*. 2021;53: 2528–  
513 2543. doi:10.3758/s13428-021-01546-0
- 514 37. Beever AT, Tripp TR, Zhang J, MacInnis MJ. NIRS-derived skeletal muscle oxidative  
515 capacity is correlated with aerobic fitness and independent of sex. *Journal of applied  
516 physiology (1985)*. 2020;129: 558–568. doi:10.1152/jappphysiol.00017.2020
- 517 38. Foulkes S, Howden E, Bigaran A, Janssens K, Antill Y, Loi S, et al. Persistent Impairment  
518 in Cardiopulmonary Fitness after Breast Cancer Chemotherapy. *Med Sci Sports Exerc*.  
519 2019;51: 1573–1581. doi:10.1249/MSS.0000000000001970

- 520 39. Niemeijer VM, Jansen JP, van Dijk T, Spee RF, Meijer EJ, Kemps HMC, et al. The  
521 influence of adipose tissue on spatially resolved near-infrared spectroscopy derived  
522 skeletal muscle oxygenation: the extent of the problem. *Physiol Meas*. 2017;38: 539–554.  
523 doi:10.1088/1361-6579/aa5dd5
- 524 40. Niemeijer VM, Spee RF, Schoots T, Wijn PFF, Kemps HMC. Limitations of skeletal  
525 muscle oxygen delivery and utilization during moderate-intensity exercise in moderately  
526 impaired patients with chronic heart failure. *Am J Physiol Heart Circ Physiol*. 2016;311:  
527 H1530–H1539. doi:10.1152/ajpheart.00474.2016
- 528 41. Jenkins DG, Quintana-Ascencio PF. A solution to minimum sample size for regressions.  
529 *PLoS One*. 2020;15: e0229345. doi:10.1371/journal.pone.0229345
- 530 42. van Hooff M, Meijer EJ, Scheltinga MRM, Savelberg HHCM, Schep G. Test-retest  
531 reliability of skeletal muscle oxygenation measurement using near-infrared spectroscopy  
532 during exercise in patients with sport-related iliac artery flow limitation. *Clin Physiol  
533 Funct Imaging*. 2022;42: 114–126. doi:10.1111/cpf.12738
- 534 43. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: A practical method for  
535 grading the cognitive state of patients for the clinician. *J Psychiatr Res*. 1975;12: 189–198.  
536 doi:10.1016/0022-3956(75)90026-6
- 537 44. Foreman MD, Fletcher K, Mion LC, Simon L. Assessing cognitive function. *Geriatr Nurs*.  
538 1996;17: 228–32; quiz 233. doi:10.1016/s0197-4572(96)80210-2
- 539 45. Foreman MD, Grabowski R. Diagnostic Dilemma: Cognitive Impairment in the Elderly. *J  
540 Gerontol Nurs*. 1992;18: 5–9. doi:10.3928/0098-9134-19920901-04
- 541 46. Mendoza T, Wang X, Cleeland C, Morrissey M, Johnson B, Wendt J, et al. The rapid  
542 assessment of Fatigue severity in cancer patients: Use of the Brief Fatigue Inventory.  
543 *Cancer*. 1999;85: 1186–1196. doi:10.1002/(SICI)1097-0142(19990301)85:5<1186::AID-  
544 CNCR24>3.0.CO;2-N
- 545 47. Chodzko-Zajko WJ, Proctor DN, Fiatarone Singh MA, Minson CT, Nigg CR, Salem GJ,  
546 et al. Exercise and Physical Activity for Older Adults. *Med Sci Sports Exerc*. 2009;41:  
547 1510–1530. doi:10.1249/MSS.0b013e3181a0c95c
- 548 48. Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee I-M, et al.  
549 Quantity and Quality of Exercise for Developing and Maintaining Cardiorespiratory,  
550 Musculoskeletal, and Neuromotor Fitness in Apparently Healthy Adults. *Med Sci Sports  
551 Exerc*. 2011;43: 1334–1359. doi:10.1249/MSS.0b013e318213febf

- 552 49. Lam KH, Kwa VIH. Validity of the PROMIS-10 Global Health assessed by telephone and  
553 on paper in minor stroke and transient ischaemic attack in the Netherlands. *BMJ Open*.  
554 2018;8: e019919. doi:10.1136/bmjopen-2017-019919
- 555 50. Katzan IL, Lapin B. PROMIS GH (Patient-Reported Outcomes Measurement Information  
556 System Global Health) Scale in Stroke: A Validation Study. *Stroke (1970)*. 2018;49: 147–  
557 154. doi:10.1161/STROKEAHA.117.018766
- 558 51. Amireault S, Godin G, Lacombe J, Sabiston CM. Validation of the Godin-Shephard  
559 Leisure-Time Physical Activity Questionnaire classification coding system using  
560 accelerometer assessment among breast cancer survivors. *Journal of cancer survivorship*.  
561 2015;9: 532–540. doi:10.1007/s11764-015-0430-6
- 562 52. Bergstrom HC, Housh TJ, Dinyer TK, Byrd TM, Jenkins NDM, Cochrane-Snyman KC, et  
563 al. Neuromuscular responses of the superficial quadriceps femoris muscles: muscle  
564 specific fatigue and inter-individual variability during severe intensity treadmill running. *J*  
565 *Musculoskelet Neuronal Interact*. 2000;20: 77–87. Available:  
566 <https://www.ncbi.nlm.nih.gov/pubmed/32131371>
- 567 53. Cortese L, Zanoletti M, Karadeniz U, Pagliuzzi M, Yaqub MA, Busch DR, et al.  
568 Performance Assessment of a Commercial Continuous-Wave Near-Infrared Spectroscopy  
569 Tissue Oximeter for Suitability for Use in an International, Multi-Center Clinical Trial.  
570 *Sensors (Basel)*. 2021;21: 6957. doi:10.3390/s21216957
- 571 54. Grassi B, Pogliaghi S, Rampichini S, Quaresima V, Ferrari M, Marconi C, et al. Muscle  
572 oxygenation and pulmonary gas exchange kinetics during cycling exercise on-transitions  
573 in humans. *J Appl Physiol*. 2003;95: 149–158. doi:10.1152/jappphysiol.00695.2002

574

575

576

### **Trial Status**

577

The trial is currently in the data collection phase with 13 participants who have

578

completed the protocol. The study is planned to continue to enroll test subjects until n = 30.

579

580 **Author Contributions**

581 Randy Hutchison: Co-Principal Investigator, NIRS expert, concept for research design and data  
582 analysis plan, contributory writer

583 Shannon Smith: Medical student researcher, supported investigator-led study design through  
584 performing literature review, assisted in pilot data collection, contributory writer

585 Chloe Caudell: Medical student researcher, supported investigator-led study design through  
586 performing literature review, assisted in pilot data collection, contributory writer

587 Sara Biddle: Data analyst, writer, researcher, contributory writer

588 W. Larry Gluck, MD: Co-Investigator, medical director of Prisma Health Cancer Institute,  
589 primary clinical contribution and oversight, contributed to conceptual study design for  
590 chemotherapy-related fatigue and mitochondrial dysfunction in patients with cancer.

591 Jennifer Trilk (corresponding author): Co-Principal Investigator, co-concept for research design  
592 and data analysis plan, co-author

	Study Period						
	Enrollment	Post Allocation					Close-out
TIMEPOINT**	-t1 (with Oncology Research Nurse)	t1 (Lactate Threshold Baseline Testing in Human Performance Lab)	t2 (baseline on-off kinetics test, pre-chemotherapy cycle 1)	t3 (pre-chemotherapy cycle 2)	t4 pre-chemotherapy cycle 3)	Etc. until chemotherapy cycles complete	Post Test
ENROLLMENT:							
Eligibility screen	x						
Informed Consent	x						
-see inclusion/exclusion criteria (Table 1)	x						
-feasibility: capable, willing to participate	x						
-Godin Leisure Survey		x					
-Ultrasound for adipose tissue thickness		x					
-Mini Mental State Exam		x					
Allocation (N/A, no intervention, observational trial only)							
INTERVENTIONS: Observational study, no interventions, gathering assessments throughout chemotherapy based on oncology prescribed, chemotherapy standard of practice							
ASSESSMENTS:							
<b>[Baseline variables]</b>							
Global Health Promis Survey		x	x	x	x	x	x

Figure 1A Schedule Enrollments

Brief Fatigue Inventory		X	X	X	X	X	X
Physical Activity		X	X	X	X	X	X
<b>[Outcome variables]</b>							
NIRS Data (O2Hb, HHb, TSI, $\tau$ , etc.)		X	X	X	X	X	X
Ventilatory Metabolic Measurements (VO <sub>2</sub> , VCO <sub>2</sub> , etc.)		X	X	X	X	X	X
Heart Rate		X	X	X	X	X	X
Rate of Perceived Exertion		X	X	X	X	X	X
<b>[Other data variables]</b>							
Height		X	X	X	X	X	X
Weight		X	X	X	X	X	X
Blood Pressure		X	X	X	X	X	X
Temperature		X	X	X	X	X	X
Ultrasound for adipose tissue thickness		X	X	X	X	X	X

Fig 1. Schedule of Enrollments, Interventions, and Assessments.

## Figure 1B Schedule Enrollments